Thomas Court
ID TEST-THOMAS-COURTLatest assessment 2025-06-06T00:00:00+00:00Messages →Report →Export summary →Decision support only. Consolidates patient data for faster physician review. It does not diagnose, recommend treatment, generate dosing, or replace physician judgment.
Primary phenotype
mitochondrial dysfunction
Recovery stage
intake only
Confidence
54/100
moderate
Clinical improvement
—
no outcomes
Phenotype profile
Clinical snapshot
mitochondrial dysfunction54%neuroinflammation
Recovery stage (derived): intake only — No follow-up outcomes recorded yet.
Top contributors: Fatigue, Post-exertional malaise, Unrefreshing sleep, Exercise intolerance, Muscle weakness
Phenotype engine
All phenotype scores
Co-infection engine
Pattern scores
bartonella0 Low
babesia21 Low
ebv10 Low
mold cirs13 Low
mcas7 Low
Lab intelligence
System concern scores
inflammatory0 Low
immune0 Low
mitochondrial0 Low
hormonal0 Low
metabolic0 Low
nutritional0 Low
detoxification0 Low
neuroinflammatory36 Mild
connective tissue8 Low
Abnormal: Citrinin (DHC) (high), Ochratoxin A (OTA) (high), Homocysteine (high), MCH (high), B. burgdorferi C6 peptide IgG (high), B. burgdorferi VlsE1 IgG (high), Streptococcal A IgG (high), Herpes simplex virus 1 (HSV-1) IgG (high), Mycoplasma pneumoniae IgG (high), Parvovirus B19 VLP VP1/Vp2 Co Capsid IgG (high), B. burgdorferi p34 (OspB) IgG (high), B. burgdorferi p39 (BmpA) IgG (high), B. burgdorferi p58 IgG (high), B. burgdorferi crude extract B31 IgG (high), B. bavariensis DbpA IgM (high), B. spielmanii DbpA IgG (high), Bartonella henselae 17 kDa IgG (high), Epstein-Barr Virus VCA gp125 IgG (high), Parvovirus B19 VLP VP2 IgG (high) · Missing: 47
Safety review
Risk flags
No safety review recorded. + Add safety screening
Outcomes
Baseline vs current
No outcome check-ins recorded.
Sources
Phenotype-relevant references
Protocol assets: IpamorelinSemaxKPVSelankBPC-157RT3TesamorelinNAD+CJC-1295EpitalonSS-31LL-37TB-500 / TB4GHK-CuAOD-9604MOTS-c
Evidence documents: SS-31: Mechanistic Overview (preclinical)MOTS-c: Mechanistic Overview (preclinical)Mitochondrial Dysfunction Phenotype: Background (observational)Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (expert_opinion)Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model.docx (expert_opinion)SLU-PP-322 — Peptide Dosing Protocols reference (expert_opinion)Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (expert_opinion)Copy of Synergistic Effects of Monolaurin, Thymosin Alpha-1, KPV, SS-31, MOTS-c, Zinc, Vitamin D3, B12, Folate, Selenium, Magnesium Glycinate, and DGL on Epstein-Barr Virus Reversal in a Murine Gammaherpesvirus 68 (MHV-68) Model.docx (expert_opinion)SS-31 — Peptide Dosing Protocols reference (expert_opinion)SS-31 — Peptide Protocol Wiki reference (expert_opinion)NAD+ — Peptide Protocol Wiki reference (expert_opinion)
Dosing references are provider-only and shown in the asset evidence / protocol context, never patient-facing.
Protocol builder
Protocol plans
- New protocol draft · draft
- Test · draft
Provider workspace
Review & notes
Current status: not started